Laurent Pharmaceuticals Inc., a biopharmaceutical company focusing on rare diseases, has received the final approval for a CAD 2.7M loan from the Quebec Government through its BioMed Propulsion program. This financing will help support the Company's Phase 2 clinical study evaluating LAU-7b in adult patients with cystic fibrosis (CF).
LAU-7b is an oral drug acting on the resolution phase of the inflammation, with the potential to treat chronic pulmonary inflammation that leads to irreversible lung damage in patients with CF. LAU-7b was also shown to enhance functional CFTR expression in CF airway cells, an effect that was further improved in the presence of a CFTR modulator.
We are very pleased with the participation from the Quebec Government through its BioMed Propulsion program, said Radu Pislariu, MD, President and CEO of Laurent Pharmaceuticals. CF is the most common fatal genetic disease affecting Canadian children and adults, with Quebec having prevalence rates that are among the highest in the world, particularly in the region of SaguenayLac-Saint- Jean region.
The Quebec government implemented the BioMed Propulsion program with the goal of supporting companies with high growth potential in Quebec's life sciences sector to help them commercialize their research findings. Of course, one of this program's objectives is to help patients suffering from diseases such as cystic fibrosis to improve their quality of life and treatment options, Mr. Pierre Fitzgibbon, Minister of Economy and Innovation, stated.
The goal of the APPLAUD trial is to evaluate LAU-7b's effect on the preservation of lung function in adult patients with CF, by reducing persistent unresolved inflammation in the lung and stimulating the return to homeostasis. LAU-7b is administered on top of the standard of care, including all commercially available CFTR modulators.
The Phase 2 study is currently enrolling patients in US...